U.S. Real Estate Stock News

What Ardelyx’s new Chief Medical Officer could mean for the pipeline Ardelyx (ARDX) has appointed Rajani Dinavahi, MD, as Chief Medical Officer, bringing more than two decades of biotechnology and clinical leadership across immuno-oncology, autoimmune disease, metabolic conditions, nephrology and transplantation. For you as a shareholder or potential investor, this kind of senior hire often matters less for today’s share price and more for how future clinical decisions, trial design and...

Investors may be wondering if Celcuity at around US$114 a share is still offering value, or if most of the upside has already been priced in. The stock has delivered a 3.6% return over the last 7 days, 5.4% over 30 days and 13.5% year to date, while the 1 year and 3 year returns are very large and the 5 year return is around 7x. Recent market attention has focused on Celcuity's position in the biotechnology space and the potential implications of its clinical and pipeline updates for long...

On March 24, 2026, Hewlett Packard Enterprise announced a broad suite of new security innovations, including HPE Juniper Networking SRX400 Series Firewalls, AI governance tools, disaster recovery enhancements, confidential computing features, and post-quantum cryptography capabilities to protect workloads across cloud, core, and edge environments. A particularly interesting element is HPE’s prompt-level AI inspection and unified, identity-based security fabric, which aim to let enterprises...

In recent weeks, American Tower highlighted its 2025 performance and 2026 priorities at an investor conference, outlined modest 2026 growth expectations, and announced a higher quarterly dividend plus authorization for US$1.60 billion in share buybacks. At the same time, Truist Financial began covering American Tower with positive commentary on its tower and data center businesses, even as the company works through revenue pressure from DISH Wireless’s default and regional headwinds in Latin...

Netflix (NFLX) shares were in focus after the latest trading session, with the stock closing at US$96.15. For investors, the question is how this price lines up with recent return trends. See our latest analysis for Netflix. The latest move comes after a mixed stretch, with a 3.42% 1 day share price return helping offset a flat 30 day patch, while the 3 year total shareholder return of about 181% points to strong longer term momentum. If Netflix has you thinking about what else is moving in...

Pitney Bowes recently launched a Temu integration within its ShipAccel cloud-based shipping and order management platform, enabling U.S. sellers to centralize Temu orders, generate shipping labels, and manage fulfillment in one place. This move highlights Pitney Bowes’ push deeper into ecommerce marketplaces by helping merchants onboard to Temu compliantly and add it as a new sales channel alongside existing platforms. We’ll now examine how this Temu integration, which ties ShipAccel more...

Valuation Snapshot After Recent Price Pullback Vipshop Holdings (VIPS) has drawn attention after recent share price weakness, with the stock down about 10% over the past month and 11% over the past 3 months, prompting fresh interest in its current valuation. See our latest analysis for Vipshop Holdings. The recent pullback fits into a weaker share price trend, with a 30 day share price return of about a 10% decline and a year to date share price return of about an 11% decline, even as the 1...

Apellis Pharmaceuticals (APLS) has drawn fresh attention after recent share price moves, prompting investors to reassess how its current valuation compares with its commercial portfolio in rare disease and eye care treatments. See our latest analysis for Apellis Pharmaceuticals. The recent one day share price return of 135.40% and 7 day share price return of 133.49% have shifted sentiment sharply. However, the 3 year total shareholder return of a 48.45% decline and 5 year total shareholder...

How Riot Platforms stock has been trading Riot Platforms (RIOT) has seen mixed recent performance, with the share price up about 4.5% over the past day but recording declines over the past week, month, and past 3 months. For context, the stock shows a return of roughly 54% over the past year, while the year to date move is a decline of about 13%. Over longer horizons, the total return is roughly 35% over 3 years and a loss of about 74% over 5 years. See our latest analysis for Riot...

KLA Corporation recently held its March 12 analyst day, reaffirming its fiscal Q3 2026 outlook, setting 2030 targets of about US$26.00 billion in revenue and US$84.00 EPS, and outlining industry tailwinds from AI-driven chip demand and advanced packaging. Around the same time, KLA also authorized an extra US$7.00 billion in share repurchases and raised its quarterly dividend by 21%, even as sector-wide worries about supply chains, regulation, and valuation pressured semiconductor equipment...

In March 2026, Electronic Arts Inc was removed from the NASDAQ Internet Index, even as the company reported strong year-over-year EPS and revenue growth. Analysts have since raised their earnings estimates for EA, suggesting the index removal coincided with improving confidence in the company’s underlying profitability profile. With analyst earnings estimates moving higher, we’ll now examine how this renewed business momentum reshapes Electronic Arts’ broader investment narrative. The...

Why Ternium (NYSE:TX) Is On Investors’ Radar Today Ternium (NYSE:TX) has drawn fresh investor attention after recent share price moves, with a 4.3% gain in the latest session and mixed returns over the past month and past 3 months. See our latest analysis for Ternium. With the share price now at US$40.15, Ternium’s recent 4.3% 1 day share price return comes after a 3.2% 7 day gain but follows a 7.6% 30 day share price decline, while the 1 year total shareholder return of 42.1% suggests...

Recently, investors have been watching Diebold Nixdorf closely as the company signaled a guidance reset alongside expectations for higher earnings and ongoing turnaround progress. This mix of optimism around digital transformation and buybacks, set against caution over backlog trends and near-term revenue, is prompting a reassessment of how durable its improvement may be. Against this backdrop of strong earnings expectations but more cautious guidance on backlog and revenue, we’ll examine...

Wondering if Gaming and Leisure Properties at around US$44.37 is offering good value right now, or if the recent weakness is a warning sign you should not ignore. The stock has slipped 3.5% over the last week and 9.3% over the last month, while the 1 year return sits at a 6.5% loss and the 5 year return at 38.4%. Recent attention on Gaming and Leisure Properties has focused on how a specialized REIT like this fits into investors' income and defensive buckets, especially with shifting...

Owens Corning recently reported quarterly results that came in below analysts’ expectations for revenue, adjusted operating income and EPS, reflecting softer market volumes. Even with this earnings miss, management pointed to higher margins and stronger operating cash flows driven by efficiency gains and a richer product mix. Next, we’ll explore how this earnings shortfall, alongside improved margins and cash generation, affects Owens Corning’s existing investment narrative. The best AI...

Core & Main (NYSE:CNM) has appointed former American Water Works CEO M. Susan Hardwick to its board, effective April 1. The company has restructured key governance roles, including a new board chair and a new audit committee chair. The longstanding executive chair has retired as part of the succession changes. Core & Main, trading at $49.4, is adjusting its leadership structure after a 3-year return of 121.8% and a 1-year return of 0.0%. The share price has seen a 2.3% decline over the past...

Ocugen (NasdaqCM:OCGN) completed enrollment and dosing early in its pivotal Phase 2/3 GARDian3 trial for OCU410ST. The trial evaluates a one time gene therapy candidate for Stargardt disease, a severe inherited retinal disorder with no approved treatments. This is Ocugen's second late stage clinical program and aligns with its stated goal to submit multiple BLAs by 2028. For readers tracking gene therapy names, Ocugen sits at the intersection of rare ophthalmology and inherited retinal...

Cogent Biosciences has completed its New Drug Application submission to the FDA for bezuclastinib in previously treated GIST, leveraging positive Phase 3 PEAK trial results and Breakthrough Therapy Designation under the Real-Time Oncology Review program. The PEAK data showed the bezuclastinib plus sunitinib regimen cut the risk of disease progression or death by half versus sunitinib alone, while maintaining a generally manageable safety profile and supporting expanded access programs for...

T. Rowe Price Group (NasdaqGS:TROW) has appointed Bill Cashel as Head of Alternatives for U.S. Wealth. The move marks a step in the firm's push into alternative investments and private market solutions. Cashel is expected to lead an expanded alternatives distribution team focused on U.S. wealth advisors. The appointment connects with offerings such as the OHA Flexible Credit Income Fund and work with Oak Hill Advisors and Goldman Sachs Asset Management. T. Rowe Price, long known for its...

UnitedHealth Group (NYSE:UNH) has settled a class-action lawsuit over denials of coverage for mental health and substance use disorder treatment. The settlement ends long running litigation related to behavioral health benefits and alleged violations of mental health parity requirements. This resolution comes as the company faces broader regulatory attention on how insurers handle behavioral health care. For investors looking at NYSE:UNH, this settlement relates directly to a core part of...

United Therapeutics recently reported that its Phase 3 TETON-1 trial of nebulized Tyvaso in idiopathic pulmonary fibrosis met the primary endpoint, showing a statistically significant improvement in lung function versus placebo over 52 weeks with no new safety issues. When combined with the earlier TETON-2 results, the data set provides two positive late-stage studies in IPF and supports United Therapeutics’ plan to seek a priority FDA review to expand Tyvaso’s labeled indications. We’ll now...

Generation Investment Management has already exited its position in Jones Lang LaSalle (JLL), citing rising competition and a belief that the company no longer stands out within commercial real estate services, while JLL’s own recent report underscores a global shortage of premium, post-2020 office space. This combination of an investor stepping back amid competitive pressures and JLL highlighting scarcity in top-tier real estate stock raises important questions about how the company’s...

Dividend policy and fresh guidance put Kanzhun in focus Kanzhun (NasdaqGS:BZ) has moved into the spotlight after its board approved an annual dividend policy, paired with new earnings guidance and detailed results for the fourth quarter and full year 2025. See our latest analysis for Kanzhun. Despite the dividend policy and earnings update drawing attention, Kanzhun’s recent share price performance has been weak, with a 30 day share price return of a 16.7% decline and a 90 day share price...

Wondering if Meritage Homes at around US$61.84 is a bargain or fairly priced? This article focuses on what the current share price might be telling you about value. The stock has returned 1.5% over the last 7 days, while the 30 day return sits at an 18.0% decline and the one year return is a 10.7% decline, despite 3 year and 5 year returns of 12.0% and 39.0% respectively. Recent attention on Meritage Homes has centered on its share price performance and how housing related names are being...